DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT07513259

Completed

Pre-Diagnosis GLP-1 Receptor Agonist Use and Post-Cancer Mortality in Adults With Obesity and Type 2 Diabetes

Pre-Diagnosis GLP-1 Receptor Agonist Use and Post-Cancer Mortality in Adults With Obesity and Type 2 Diabetes: A Target Trial Emulation

Asset

GLP-1 / incretin class catch-all

Listed sites

1

Recruiting sites

—

Enrollment

203,424

actual

Study population

Obesity / overweight, Oncology, Type 2 diabetes

Key I/E criterion

•BMI ≥27

Primary endpoint

•All-cause death

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07513259
Org study IDCS2-24004

Timeline

Milestones

Study start2018-01-01actual
Primary completion2025-10-31actual
Study completion2025-10-31actual
Study first posted2026-04-07actual
Last update posted2026-04-07actual

Assets

Investigational agents

GLP-1 / incretin class catch-all

Study populations

Who this study enrolls

Obesity / overweightOncologyType 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted
Sampling methodNon probability sample

Study population text

Adults will be selected from the TriNetX US Collaborative Network, a distributed database of de-identified electronic health records contributed by participating healthcare organizations across multiple clinical systems and practice settings. The study population consists of adults with obesity and type 2 diabetes who received routine clinical care in this network and were identified through diagnosis records, body mass index data, and medication prescribing data. Comparator-specific cohorts were defined within this source population to evaluate pre-diagnosis glucose-lowering treatment strategies before obesity-associated cancer diagnosis.

Inclusion criteria

•Adults aged 18 years or older
•BMI ≥27 kg/m2, or diagnosis codes consistent with obesity
•Type 2 diabetes mellitus
•Initiation of a glucose-lowering medication before obesity-associated cancer diagnosis
•Incident obesity-associated cancer diagnosed after medication initiation
•No dispensing of the study drug class during the 6-month washout period before the first qualifying prescription

Exclusion criteria

•Type 1 diabetes mellitus, Other specified diabetes types that are not type 2 diabetes
•Human immunodeficiency virus infection
•End-stage renal disease
•Prior bariatric surgery
•Prior organ transplantation
•Transplant-related complications
•Any use of tirzepatide before cohort entry

Endpoints (5)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other clinical outcomes
3
Cardiovascular outcomes
2

Cardiovascular outcomes

2 endpoints
Primary/protocol endpoint

All-Cause Mortality

Time frame:Up to 36 months after obesity-associated cancer diagnosis

All-cause death

time to event, event

SNOMED 419620001

Secondary/protocol endpoint

All-Cause Inpatient Hospitalization

Time frame:Up to 36 months after obesity-associated cancer diagnosis

All-cause hospitalization

time to event, event

Other clinical outcomes

3 endpoints
Secondary/protocol endpoint

Sepsis

Time frame:Up to 36 months after obesity-associated cancer diagnosis

time to event, event

Secondary/protocol endpoint

Pulmonary Embolism

Time frame:Up to 36 months after obesity-associated cancer diagnosis

time to event, event

Secondary/protocol endpoint/low confidence

Pericardial Effusion

Time frame:Up to 36 months after obesity-associated cancer diagnosis

time to event, event

Publications (38)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.